DOW Module 1 Midpoint Quiz
Breast cancer staging helps to define:
Severity of disease
Goals of therapy
Location of disease in the body
All of the above
Progesterone status often is related to HER2 status.
True
False
Which of the following is true?
CMF is a low-emetogenic regimen.
In CMF, cyclophosphamide is dosed at 400mg/m2
Methotrexate can cause GI toxicity
CMF is preferred as first line therapy.
For which of the following receptor statuses is Faslodex appropriate?
HR(-) HER2(-)
HR(-) HER2(+)
HR(+) HER2(+)
HR(+) HER2(-)
Trastuzumab (Herceptin) is ONLY indicated for HER2+ breast cancer.
True
False
Which of the following is dosed at 3.6 mg/kg every 3 weeks?
Enhertu
Kadcyla
Trodelvy
Padcev
True or False: Enhertu is given until progression free survival.
True
False
AB is scheduled to begin Trodelvy C1D1 on 10/22. On what day should AB receive Neulasta OBI?
10/22
10/23
10/29
10/30
Which regimen matches the following description: 1. Is a preferred regimen to treat early-stage, triple negative breast cancer. 2. Can be given as a neoadjuvant or adjuvant therapy 3. Requires monitoring for cardiotoxicity 4. Requires dose adjustment for hepatic dysfunction
Herceptin + Perjeta
AC
Ado-trastuzumab Emtansine
CMF
{"name":"DOW Module 1 Midpoint Quiz", "url":"https://www.quiz-maker.com/QEZ5AZ3XN","txt":"Breast cancer staging helps to define:, Progesterone status often is related to HER2 status., True or False: Enhertu should be mixed in PPR. Explain your answer.","img":"https://www.quiz-maker.com/3012/CDN/70-3144637/calender.png?sz=1200"}